31-DEC-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3855 312 189 98 30 2 02/06/2019 484 193
Screened at PD     1384 144 105 60 14 0      
Pre-Screened prior to PD     2454 151 73 32 12 1      
Treatment-naive     17 17 11 6 4 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     521 25 14 7 1 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2056 303 141 77 27 2      
Screened at PD     1157 166 103 59 21 1      
Pre-Screened prior to PD     827 117 27 11 2 0      
Treatment-naive     16 16 10 6 3 1      
After PD on a Lung_MAP Sub-Study     56 4 1 1 1 0      
 
Sub-Study Assignments (open studies only)
S1800E     269 269 124 67 23 1      
S1900G     33 6 2 1 0 0      
S1900J     15 7 3 2 1 0      
S1900K     29 21 12 7 3 1      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     566 71 56 29 12 1      
Initial sub-study registrations     554 71 56 29 12 1      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 48 48 45 23 10 0 05/22/2025 332 109
Docetaxel plus Ramucirumab Y   25 25 24 12 5 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   23 23 21 11 5 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 23 6 2 1 0 0 05/05/2023 352 115
Capmatinib + Osimertinib + Ramucirumab Y   13 5 2 1 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 2 1 1 0 0 11/19/2024 251 83
Amivantamab Hyaluronidase Y   3 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 18 15 8 4 2 1 08/08/2024 283 94
Tepotinib + Ramucirumab Y   11 9 4 2 1 1      
Tepotinib Y   7 6 4 2 1 0